THERAPEUTIC BIOSAMPLE OWNERSHIP DISPUTES IN RUSSIA

1. INTRODUCTION

Therapeutic biosample ownership disputes concern legal disagreements over the collection, possession, storage, use, transfer, commercialisation, and disposal of biological materials obtained from human beings for therapeutic, diagnostic, or research purposes. Such materials include blood, tissues, cells, bone marrow, reproductive materials, tumour specimens, stem cells, and genetically derived biological samples.

In Russia, these disputes arise particularly in connection with biobanks, regenerative medicine, transplantation, personalised medicine, cell-based therapies, genomic research, and pharmaceutical development.

The central legal question is whether a biological sample belongs to the patient, the medical institution, the research organisation, or another authorised entity. Russian legislation does not establish one comprehensive ownership regime for every category of human biosample. Instead, the legal position depends on medical consent, personal information protection, contractual arrangements, healthcare legislation, civil-law principles, and specialised rules governing biological materials.

2. LEGAL AND REGULATORY FRAMEWORK IN RUSSIA

A. CONSTITUTION OF THE RUSSIAN FEDERATION, 1993

The Constitution establishes fundamental protections relevant to human biological materials.

Article 20 protects the right to life.

Article 21 protects human dignity and personal integrity.

Article 23 protects privacy and personal and family confidentiality.

Article 24 restricts the collection, storage, use, and dissemination of information concerning private life without the legally required consent.

Article 41 establishes the right to healthcare.

These provisions are important when determining the extent to which biological materials and associated personal information may be collected, retained, and used.

B. FEDERAL LAW NO. 323-FZ OF 21 NOVEMBER 2011 ON THE FUNDAMENTALS OF PROTECTING CITIZENS' HEALTH

This legislation is central to therapeutic biosample governance.

Relevant provisions include:

Article 13: Medical confidentiality.

Article 20: Informed voluntary consent to medical intervention and refusal of medical intervention.

Article 22: Patient rights concerning medical information.

Article 47: Donation of organs and tissues and their transplantation.

Article 48: Medical consultation and medical commissions.

The law establishes important requirements concerning patient consent, medical confidentiality, and the lawful use of human biological materials in healthcare.

C. FEDERAL LAW NO. 152-FZ OF 27 JULY 2006 ON PERSONAL DATA

This legislation governs the processing of personal information associated with biosamples.

Genetic and medical information may constitute sensitive personal data and require appropriate legal grounds and safeguards.

Relevant issues include:

Lawful processing of personal data.

Consent requirements where applicable.

Confidentiality obligations.

Data security.

Restrictions on unauthorised disclosure.

Rights concerning personal information processing.

D. FEDERAL LAW NO. 180-FZ OF 23 JUNE 2016 ON BIOMEDICAL CELL PRODUCTS

This legislation is particularly important for therapeutic biosamples used in cellular medicine.

It regulates biomedical cell products, including their development, expert assessment, registration, production, storage, and application.

It provides a specialised legal framework for the handling of biological materials used in advanced therapeutic applications.

E. FEDERAL LAW NO. 4180-I OF 22 DECEMBER 1992 ON TRANSPLANTATION OF HUMAN ORGANS AND (OR) TISSUES

This legislation governs the transplantation of human organs and tissues.

It establishes restrictions and safeguards concerning organ and tissue donation, procurement, and transplantation. Its provisions are particularly relevant when disputes concern human tissues intended for therapeutic transplantation.

F. CIVIL CODE OF THE RUSSIAN FEDERATION

The Civil Code provides general principles concerning property, contractual obligations, compensation, and protection of personal rights.

Relevant provisions include Articles 128, 209, 218, 309, 393, 1064, and 150–152.2.

However, the application of ordinary property rules to human biological materials is not automatic. Human dignity, medical consent, statutory restrictions, and the special character of biological materials may limit conventional ownership claims.

3. LEGAL NATURE OF THERAPEUTIC BIOSAMPLE OWNERSHIP

Therapeutic biosample disputes involve several distinct legal interests.

A. PATIENT'S INTEREST

Patients may possess legally protected interests concerning bodily integrity, consent, confidentiality, and decisions about medical interventions involving their biological materials.

However, these interests do not necessarily establish unrestricted ownership of every separated biological specimen.

B. MEDICAL INSTITUTION'S INTEREST

Medical institutions may lawfully possess and retain biosamples for authorised medical purposes, including diagnosis, treatment, storage, and legally permitted research.

Possession or custody does not automatically establish unrestricted ownership.

C. RESEARCH INSTITUTION'S INTEREST

Research institutions may obtain lawful rights to use biosamples under consent documents, research agreements, institutional approvals, and applicable legislation.

Such rights remain subject to the scope of authorisation and relevant privacy and healthcare requirements.

D. COMMERCIAL ENTITY'S INTEREST

Biotechnology companies may participate in developing therapeutic products using biological materials.

Their commercial interests may involve manufacturing processes, intellectual property, technological improvements, and contractual rights. These interests do not automatically confer ownership of the original human biological material.

4. COMMON OWNERSHIP DISPUTES

A. PATIENT VERSUS HOSPITAL

Disputes may arise when patients request the return or destruction of stored biological samples, while hospitals claim that continued retention is necessary for medical documentation, safety, or regulatory compliance.

The outcome depends on the nature of the material, applicable retention requirements, and the patient's legal rights.

B. PATIENT VERSUS RESEARCH INSTITUTION

Disputes may occur when biological samples collected for treatment are subsequently proposed for scientific research.

The central issue is whether the original consent authorises the additional purpose or whether further consent or another legal basis is required.

C. BIOBANK VERSUS BIOTECHNOLOGY COMPANY

Biobanks and commercial biotechnology organisations may disagree over access rights, sample transfers, intellectual property, commercial benefits, and restrictions imposed by donor consent.

D. FAMILY MEMBERS VERSUS MEDICAL INSTITUTIONS

Following a patient's death, disputes may arise concerning stored tissues, reproductive materials, or other biological specimens.

The legal outcome depends on the particular material, applicable statutory rules, documented consent, and the rights recognised under Russian law.

5. CONSENT AND BIOSAMPLE TRANSFER REQUIREMENTS

The lawful handling of therapeutic biosamples requires attention to the following:

Informed Consent: Medical interventions and relevant sample collection must comply with applicable consent requirements.

Purpose Limitation: Samples should not be used beyond the legally authorised purposes.

Confidentiality: Medical and genetic information must receive appropriate protection.

Storage Conditions: Institutions must comply with applicable technical and regulatory requirements.

Transfer Agreements: Transfers between institutions should specify permitted uses, custody, confidentiality, and responsibilities.

Commercialisation: Commercial activities must comply with applicable legal restrictions and contractual obligations.

Withdrawal of Consent: The consequences of withdrawal depend on the legal basis of processing, the type of material, and applicable retention requirements.

Disposal: Biological materials must be handled and disposed of according to relevant medical, sanitary, and regulatory standards.

6. RELEVANT JUDICIAL DECISIONS AND CASE LAWS

Russian reported judicial decisions specifically addressing ownership disputes over therapeutic human biosamples remain limited. Therefore, the following decisions provide relevant principles concerning bodily autonomy, medical consent, privacy, property, and biological-material regulation. Foreign decisions are identified separately and should not be treated as binding Russian authorities.

1. S. and Marper v. United Kingdom (2008), European Court of Human Rights

The Grand Chamber examined the retention of fingerprints, cellular samples, and DNA profiles by public authorities.

The Court held that the retention of cellular samples and DNA information engaged the right to private life under Article 8 of the European Convention on Human Rights.

The judgment is highly relevant to disputes concerning the continued retention and use of human biosamples without adequate legal safeguards.

Authority: Analogous authority on biological sample retention and privacy.

2. Evans v. United Kingdom (2007), European Court of Human Rights

The Court considered disputes involving stored embryos and reproductive autonomy.

The judgment demonstrates the importance of consent, reproductive interests, and the competing rights of individuals concerning stored biological materials.

Authority: Analogous authority on reproductive biosample disputes.

3. Parillo v. Italy (2015), European Court of Human Rights

The Court considered whether an individual could donate embryos created through assisted reproduction for scientific research.

It examined the relationship between personal autonomy, human biological materials, and the legal restrictions imposed on embryo use.

The decision is relevant to disputes over the permitted purposes for which stored human biological materials may be used.

Authority: Analogous authority on embryo ownership and research use.

4. Moore v. Regents of the University of California (1990), Supreme Court of California

The court considered whether a patient retained a proprietary claim over removed cells subsequently used in commercial research.

The court rejected the patient's conversion claim under the applicable California law but recognised potential liability for failure to disclose material conflicts of interest.

The judgment illustrates the distinction between ownership of biological specimens, informed consent, and commercial research interests.

Authority: Analogous comparative authority; not binding in Russia.

5. Yearworth v. North Bristol NHS Trust (2009), Court of Appeal of England and Wales

The court considered ownership claims involving sperm samples stored for future medical use.

It recognised that the claimants possessed proprietary interests in the stored samples under the circumstances of the case.

The decision is relevant to disputes involving the custody, control, and intended therapeutic use of stored reproductive materials.

Authority: Analogous comparative authority; not binding in Russia.

6. Washington University v. Catalona (2007), United States Court of Appeals for the Eighth Circuit

The court examined ownership and control disputes involving biological specimens donated for medical research.

It considered the legal consequences of donation agreements and institutional control over stored specimens.

The judgment provides useful comparative principles for biobank governance and biosample transfer agreements.

Authority: Analogous comparative authority; not binding in Russia.

LEGAL SIGNIFICANCE: These decisions provide comparative judicial principles rather than direct Russian precedents. Their relevance is persuasive and analytical only, subject to Russian constitutional and statutory law.

7. LIABILITY AND DISPUTE RESOLUTION

Institutions may face legal consequences where biosamples are unlawfully collected, transferred, retained, disclosed, or used.

Potential liabilities include:

Civil liability for infringement of legally protected rights.

Compensation for proven losses and legally recognised non-pecuniary harm.

Administrative liability for violations of personal-data requirements.

Regulatory sanctions for non-compliance with healthcare legislation.

Contractual liability for breach of sample-transfer or research agreements.

Criminal liability where the conduct independently satisfies the elements of a criminal offence.

Disputes may be addressed through negotiations, institutional complaint mechanisms, regulatory proceedings, and judicial litigation.

8. PRACTICAL COMPLIANCE REQUIREMENTS

Russian hospitals, biobanks, research organisations, and biotechnology companies should implement the following safeguards:

Maintain documented biosample collection and consent records.

Clearly distinguish medical treatment from secondary research purposes.

Establish legally compliant sample ownership and custody arrangements.

Maintain accurate biosample identification and traceability systems.

Implement access controls for genetic and medical information.

Establish written agreements governing transfers between institutions.

Define retention, withdrawal, and disposal procedures.

Document commercial and intellectual property arrangements.

Establish procedures for responding to patient complaints.

Conduct periodic legal and regulatory audits.

9. CONCLUSION

Therapeutic biosample ownership disputes in Russia involve a complex relationship between human dignity, bodily autonomy, medical consent, privacy, property principles, and biotechnology commercialisation. Russian law does not establish a single unrestricted ownership model applicable to all human biological materials. Instead, the legal rights of patients, hospitals, research institutions, and biotechnology companies depend on the type of sample, its intended purpose, statutory restrictions, consent documentation, and contractual arrangements. Federal Laws No. 323-FZ, No. 152-FZ, No. 180-FZ, and No. 4180-I provide important components of the regulatory framework. Comparative decisions such as S. and Marper, Evans, Parillo, Moore, Yearworth, and Washington University v. Catalona demonstrate the importance of consent, privacy, custody, and lawful sample use. Effective biosample governance therefore requires transparent consent procedures, clear contractual allocation of responsibilities, secure storage, lawful secondary use, and respect for the rights of individuals from whom biological materials originate.